Fatty Liver (NAFLD/MASLD) Screening in China: FibroScan, Ultrasound & Liver Panel

Fatty liver disease has become one of the most prevalent chronic health conditions in the world — yet most people who have it don't know. Non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) under updated nomenclature, affects an estimated 25% of the global adult population. In many cases it's completely silent: no symptoms, normal how-you-feel health, normal digestion — and a liver progressively accumulating fat that can, over years, lead to inflammation (NASH/MASH), fibrosis, cirrhosis, and liver cancer.

The good news is that NAFLD is highly detectable with the right combination of non-invasive tools. This article explains what those tools are, who should consider them, and how to access a comprehensive fatty liver assessment in China at a fraction of Western prices.

What Fatty Liver Screening Involves

A complete fatty liver workup uses several complementary approaches, because no single test tells the whole story:

Liver Ultrasound

Abdominal ultrasound is the first-line imaging tool for detecting hepatic steatosis (fat accumulation in liver cells). When the liver contains excess fat, its echogenicity on ultrasound increases — it appears brighter than the kidney and surrounding tissue (hepatorenal echo contrast). Ultrasound can detect moderate-to-severe fatty liver reliably, is non-invasive, widely available, and inexpensive.

Limitations: Ultrasound is less sensitive for mild steatosis (typically below 20–30% fat content), and it cannot accurately quantify the degree of fat or assess fibrosis (scarring). This is why FibroScan adds significant value.

FibroScan (Transient Elastography with CAP)

FibroScan is a specialized ultrasound-based device that measures two things simultaneously:

1. Liver stiffness (LSM — Liver Stiffness Measurement): A vibration is sent into the liver, and the speed at which the wave travels through the tissue is measured. Stiffer tissue = more fibrosis. This provides a fibrosis stage estimate (F0–F4 on the METAVIR scale), from no fibrosis (F0) through cirrhosis (F4) — without a needle biopsy.

2. CAP (Controlled Attenuation Parameter): Simultaneously quantifies the degree of steatosis (fat content) in decibels per meter. CAP grades steatosis from S0 (no significant steatosis) through S3 (severe steatosis), giving a more precise picture than ultrasound alone.

The procedure is entirely non-invasive: you lie on your back, raise your right arm, and a probe is placed between the ribs. The whole procedure takes about 10 minutes. FibroScan is the single most clinically useful non-invasive tool for characterizing both fatty liver severity and fibrosis simultaneously, making it the most important advancement in non-invasive liver assessment in recent decades.

Clinical significance of FibroScan results: Liver stiffness below 7 kPa in most contexts suggests no significant fibrosis; values above 9–12 kPa raise concern for advanced fibrosis; values above 12–15 kPa are concerning for cirrhosis. These thresholds vary somewhat by etiology and should be interpreted by a physician in clinical context.

Liver Function Tests (LFT Panel)

A blood panel measuring ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase), GGT (gamma-glutamyl transferase), total bilirubin, albumin, and total protein.

In NAFLD:
- ALT and AST are often mildly elevated, reflecting hepatocyte injury — but they're normal in a significant proportion of people with fatty liver, which is why liver enzymes alone are an insufficient screen.
- GGT is particularly sensitive to metabolic liver stress and alcohol-related injury.
- Albumin and bilirubin are markers of liver synthetic function — in early fatty liver they're typically normal; abnormalities suggest more advanced disease.

FIB-4 Score and Other Non-Invasive Fibrosis Indices

Using the blood results (ALT, AST, platelet count, and age), clinicians can calculate the FIB-4 score — a validated non-invasive fibrosis index that helps stratify risk of advanced fibrosis. FIB-4 below 1.3 has a high negative predictive value for advanced fibrosis in most populations. It's a useful tool when used alongside FibroScan rather than in isolation.

Metabolic Markers: Lipid Profile, Fasting Glucose, HbA1c

NAFLD is tightly linked to metabolic syndrome — the constellation of insulin resistance, obesity, dyslipidemia, and hypertension. A complete fatty liver assessment includes:

• Fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) — elevated triglycerides and low HDL are common in NAFLD
• Fasting glucose and HbA1c — insulin resistance is both a cause and consequence of fatty liver; diabetes doubles the risk of NAFLD progressing to NASH

These markers inform whether NAFLD is occurring in a metabolically favorable or unfavorable context, which matters for prognosis and management.

Upper Abdominal MRI

For cases where FibroScan and ultrasound findings are equivocal, or where a liver lesion needs further characterization, upper abdominal MRI provides higher resolution imaging. MRI can detect lesions smaller than 1 cm, characterize liver lesions with greater specificity than ultrasound, and provide hepatic fat quantification via MRI-PDFF (proton density fat fraction) — considered the most accurate non-invasive fat quantification method.

The GI & Digestive Health Screening package includes upper abdominal MRI as part of the comprehensive bundle.

Who Should Get Screened for Fatty Liver

The following groups should consider active NAFLD/MASLD screening:

• Type 2 diabetes or pre-diabetes — insulin resistance is the strongest risk factor for NAFLD progression to NASH and fibrosis
• Metabolic syndrome — defined as three or more of: abdominal obesity, elevated triglycerides, low HDL, elevated blood pressure, elevated fasting glucose
• Obesity (BMI ≥ 30) or central obesity (large waist circumference) — especially with no recent liver assessment
• Elevated liver enzymes on a routine blood test — even mildly elevated ALT or AST warrants investigation to exclude fatty liver and other causes
• Family history of liver disease, cirrhosis, or hepatocellular carcinoma
• Regular alcohol consumption — even below clinical heavy-drinking thresholds, alcohol compounds steatosis risk
• Age over 45 with metabolic risk factors and no recent liver assessment
• Known fatty liver on prior imaging with no follow-up assessment of fibrosis stage

If you've been told your liver is "a bit fatty" on an ultrasound but never had fibrosis staging, this is an important gap: steatosis alone carries different prognosis than steatohepatitis with fibrosis, and the distinction requires FibroScan or biopsy.

Why Get Screened in China

Cost and access to FibroScan

In the United States, FibroScan availability varies widely by region — many community gastroenterology practices don't have the device, requiring referral to a specialist center. When available, the scan plus office consultation can cost $500–$1,500+ out-of-pocket. Combined with abdominal MRI, LFT panel, and metabolic blood work, assembling a comprehensive fatty liver assessment in the US or UK typically involves multiple appointments over weeks.

The GI & Digestive Health Screening package at $799 bundles FibroScan, liver ultrasound, upper abdominal MRI, full LFT panel, lipid profile, glucose/HbA1c, and more in a single visit — at a cost that compares favorably to the US price of FibroScan and one blood panel alone.

Same-day comprehensive assessment

Getting FibroScan, liver ultrasound, abdominal MRI, and blood work done on the same day means you receive a coherent clinical picture interpreted together, not a series of piecemeal results from different providers without coordinated interpretation.

Modern liver imaging centers

Major Chinese hospitals have adopted FibroScan widely — it's considered standard assessment at GI and hepatology departments. The Chinese population has a high prevalence of hepatitis B, meaning Chinese hepatologists have extensive experience with liver fibrosis assessment and liver disease management.

How the Process Works with SinoCareLink

SinoCareLink coordinates English-speaking patients through the logistics of accessing Chinese healthcare — we're a coordination service, not a medical provider.

1. Free consultation — We discuss your risk factors, existing results, and what you're trying to determine. Fatty liver investigation or general metabolic health assessment can both be covered.
2. Package coordination — We confirm the appropriate package components and arrange scheduling. For FibroScan, a brief fast (typically 2 hours) is required; the coordinator will walk you through the preparation.
3. On-site support — A bilingual companion accompanies you throughout the visit — registration, blood draw, imaging suite, physician consultation. Nothing gets lost in translation.
4. Results delivery — All results are translated into English. FibroScan and ultrasound results are available same-day; blood work within 24–48 hours; MRI report within a few days.
5. Follow-up coordination — If advanced fibrosis is identified or liver lesions require further characterization, we coordinate specialist follow-up — whether in China or with guidance for home-country management.

Frequently Asked Questions

What is the difference between NAFLD and NASH?
NAFLD (non-alcoholic fatty liver disease) is the umbrella term for liver fat accumulation not caused by significant alcohol use. NASH (non-alcoholic steatohepatitis) is a subtype where fat accumulation has triggered liver cell inflammation and damage — a more serious stage that significantly increases the risk of fibrosis progression, cirrhosis, and liver cancer. FibroScan helps distinguish no/minimal fibrosis (typical of simple steatosis) from more advanced fibrosis (associated with NASH), without a biopsy.

Can fatty liver be reversed?
Yes — and this is one of the most important reasons to catch it early. In its early stages (before significant fibrosis develops), NAFLD is largely reversible through weight loss, dietary change (particularly reduced refined carbohydrates and fructose), exercise, and metabolic management. Even 7–10% body weight loss in overweight individuals can significantly reduce liver fat. Once fibrosis advances toward cirrhosis, reversal becomes much more limited.

My routine liver enzymes were normal — could I still have fatty liver?
Yes. Studies show that a significant proportion of people with histologically confirmed NAFLD — including some with NASH and even early fibrosis — have normal ALT and AST levels. Normal liver enzymes do not rule out fatty liver or its progression. This is why imaging (ultrasound, FibroScan) is part of a complete assessment, not just blood tests.

What does FibroScan feel like?
The FibroScan probe is pressed between the ribs on the right side with light pressure. You'll feel a mild painless vibration. The whole procedure takes about 10 minutes. There's no preparation beyond a 2-hour fast, no needles, no discomfort. Results are available immediately.

Do I need to stop alcohol before FibroScan?
Ideally, avoid alcohol for at least 24 hours before FibroScan, as recent alcohol consumption can temporarily increase liver stiffness and produce falsely elevated fibrosis readings. For the LFT panel, the same applies.

What happens if advanced fibrosis or cirrhosis is suspected?
If FibroScan results suggest advanced fibrosis (F3) or cirrhosis (F4), the gastroenterologist will typically recommend specialist hepatology consultation, assessment for complications, and liver cancer surveillance. SinoCareLink can coordinate an in-person specialist consultation during the same trip or arrange a teleconsultation follow-up. Having all the scan data and blood work already done means the specialist consultation is efficient.

Is the FibroScan accurate if I'm overweight?
FibroScan accuracy can be reduced in patients with high BMI (particularly above 30–35) due to difficulty placing the probe optimally between the ribs. Major Chinese hospitals use the XL probe specifically designed for patients with larger waists, which extends the reliable measurement range. This will be confirmed at coordination stage.